Neuropathy News ® Together, we can beat this disease Issue 29: 1-08 – January Issue IN THIS ISSUE Clinical Trials Research Update . . . . . . . . . . . . . . . . . .1 Letter From the President . . . . . . . . . . . . . . . . . . . . . .3 Better Safe Than Sorry . . . . . . . . . . . . . . . . . . . . . . . . .3 Association Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 EDITOR Tina Tockarshewsky 2007 Benefactor Listing . . . . . . . . . . . . . . . . . . . . . . . .5 ASSOCIATE EDITORS Irene H. Beer, Natacha T. Pires Neuropathy Center News . . . . . . . . . . . . . . . . . . . . . .6 MEDICAL ADVISOR Norman Latov, M.D., Ph.D. Supporting Support Groups: Part I . . . . . . . . . . . . . . .6 Support Group Directory . . . . . . . . . . . . . . . . . . . . . .8 Optimizing Wellness: Part II . . . . . . . . . . . . . . . . . . .11 Letters to the Editor . . . . . . . . . . . . . . . . . . . . . . . . . .12 Ask the Doctor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 Safe Driving . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 FDA Exchange . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15 Clinical Trials: The Path to Emerging Peripheral Neuropathy Treatments BY THOMAS H. BRANNAGAN, III, M.D., WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Despite the fact that approximately 20 million people in the U.S. alone have peripheral neuropathy, treatment options are extremely limited. Right now patients only have two FDA-approved medications indicated for neuropathy: pregabalin (indicated for diabetic neuropathy and postherpetic neuralgia) and duloxetine (indicated for diabetic neuropathy only). Both will treat the symptoms of neuropathy pain, but not the neuropathy itself. However, there is hope for additional treatment possibilities on the horizon. Currently, a number of medications are in clinical trials to treat peripheral neuropathy, and their outcomes may soon provide new treatment options for physicians. Diabetic Neuropathy The most common cause of neuropathy is diabetes. Given its prevalence, there is more clinical trial activity for diabetic neuropathy than for any other neuropathy. Trials in progress include: • Gene Therapy Treatment One potential treatment for diabetic neuropathy under investigation is gene therapy to increase vasoactive endothelial growth factor (VEGF). VEGF is a glycoprotein growth factor known to stimulate endothelial cells or blood vessels, though it has subsequently been found to also act on neuronal growth. In 2001, Dr. Drasko Simovic and his research team at Tufts University School of Medicine reported that gene therapy to promote VEGF helped neuropathy associated with vascular disease, including some patients with diabetes. VEGF gene therapy has also been successful in improving diabetic neuropathy in animal models. Today, there are several studies enrolling neuropathy patients for VEGF gene therapy, each with different methods of delivering a gene to promote VEGF expression. • Aldose Reductase Inhibitors Another possible treatment for diabetic neuropathy is the development of medications inhibiting or blocking the aldose reductase enzyme. Aldose reductase is an enzyme that converts glucose to sorbitol. It is thought that the flux of the glucose to sorbitol conversion contributes to the nerve damage found in diabetic neuropathy. Previous attempts at developing aldose reductase inhibiting medications have been unsuccessful because of weak activity by or side effects from the studies’ medicines. However, newer medications with stronger activity against aldose reductase have since been developed, and these show promise in small initial studies. Results of further studies are awaited to see if this early promise continues. Inherited Neuropathy Inherited neuropathy or Charcot Marie Tooth (CMT) disease is another common cause of neuropathy. Progress has been made in identifying some of the genetic mutations responsible for CMT, however, the find(continued on page 2) Neuropathy News January 2008 Update on Current Clinical Trials in Neuropathy Research ings have not translated easily into new therapies. One finding does show promise, though. Using the genetic mutations identified, scientists can now create animal models for CMT. The most common cause of CMT is the presence of an extra copy of the PMP22 gene. Vitamin C acts to reduce the expression of this gene, and investigators have recently found that administering high doses of vitamin C improved the neuropathy in these animal models. Separate clinical studies are now being conducted in the Netherlands, Italy and the U.S. to evaluate the efficacy of high dose vitamin C therapy for CMT type I. Auto-Immune Neuropathy Anti-Mag (myelin associated glycoprotein) neuropathy typically presents as a slowly progressive demyelinating neuropathy, causing unsteadiness when walking as well as weakness. At the 2007 American Academy of Neurology annual meeting, Dr. Marinos C. Dalakas of Jefferson Medical College and his research colleagues reported on the benefit of rituximab for anti-Mag neuropathy in a placebo-controlled double-blind randomized trial. Rituximab is an intravenous medication that kills the B cells involved with the production of antibodies (including the anti-Mag antibody). The benefits of rituximab were found to last six to eight months. Neuropathic Pain The symptomatic medications currently available for neuropathic pain do help many people. Still, other patients find them to be ineffective or THE NEUROPATHY ASSOCIATION Board of Directors Ronnie Chalif, President Michael Sloser, Treasurer Jill C. Lesser, Esq., Secretary Norman Latov, M.D., Ph.D., Medical Advisor Arthur W. Collins, Ph.D. James R. Gardner, Ph.D. Bartley R. Labiner, D.D.S. Jan R. Martin Peter Tishman David Wood Past President Mary Ann Donovan (1995-2005) Executive Director Tina Tockarshewsky 2 continued from page 1 cause intolerable side effects. There continues to be a need for new neuropathic pain medications. Several medications that act by new nerve pain mechanisms have recently been developed and are being tested. Dextromethorphan hydrobromide/quinidine sulfate (DMQ) blocks the Nmethyl-D-aspartate (NMDA) receptor used by the excitatory transmitter glutamate: a study presented at the 2007 International Congress on Neuropathic Pain reported that DMQ helped diabetic neuropathy pain. In addition, a novel anti-convulsant called lacosamide, which acts by modulating slow sodium channels, was recently reported in the Clinical Journal of Pain as improving diabetic neuropathy pain. Presently, lacosamide is under review with the European Medicines Agency (EMEA) and the FDA for use in diabetic neuropathy pain treatment. The peripheral neuropathy community looks with great hope to the results of current and future clinical trials, knowing that they serve as harbingers of hope for better care and treatment. Patients interested in learning about or participating in a clinical trial can ask their own physicians or learn more about current trials on the National Institutes of Health (NIH)-sponsored website, www.clinicaltrials.gov. Dr. Thomas Brannagan is the director of the diabetic neuropathy research center at Weill Cornell Medical College. www.med.cornell.edu/diabeticneuropathy Directors Emeriti Lovejoy Duryea John P. Warwick National Advisory Council Paul G. Donohue, M.D. Jonathan Fanton George Fisher General (Ret.) P.X. Kelley Walter L. Larimore, M.D. Heidi Loeb Walter G. Montgomery Sheila S. Mosler Vincent “Jim” Peters Thomas Moran Charles Ryskamp Judith P. Sulzberger, M.D. Published by The Neuropathy Association, Inc. 60 E. 42nd St., Suite 942 New York, NY 10165-0930 Tel: 212-692-0662 Fax: 212-692-0668 Website: www.neuropathy.org E-mail: [email protected] Back issues: $3.00 each Set of 28 (Issues 1-27): $68.00 If you have two addresses, please send us both your primary and secondary addresses with the dates you’ll be there, so we can send your mail to the right place. If you move, please send us your new address. Neuropathy News January 2008 Letter from the President Excitement fills the air as we enter 2008! Peripheral neuropathy awareness has gained great momentum as our Association continues to serve the neuropathy community by forging ahead with new strength in leadership and solid growth through our nationwide network of centers and support groups. Neuropathy is indeed emerging from the shadows and finding its way into public consciousness. I even heard it mentioned during conversation at the theater the other night; then, again, a few days later at a dinner party. Lately, everywhere I go I encounter people sharing a neuropathy story. While more people know what peripheral neuropathy is, few really understand what it feels like or means to have neuropathy. That is our next challenge. Great strides continue to be made in the quest for new treatments for the myriad of causes for neuropathy effecting around 20 million people in the U.S. alone. We are doing our part to make that happen by growing our Association, with approximately 50,000 members and supporters, 120 support groups, four chapters and eight neuropathy centers spanning North America. We look forward to launching new initiatives in your local community and across the nation. How wonderful to have a new year ahead filled with new hope and endless possibilities. Together, we can—and we will—beat neuropathy! Sincerely, Ronnie Chalif The Neuropathy Association continues to work to serve those living with neuropathy. A testament to our recent efforts in education and awareness was the prestigious Bronze Telly Award we received last year for our first television public service announcement—featuring Angela Lansbury—on peripheral neuropathy. We have expanded our affiliate network of Neuropathy Centers, which provide hope and help, plus offer neuropathy patients a more concentrated effort in the services they need. We are grateful for the unwavering dedication over the past year of our staff, including our new Executive Director Tina Tockarshewsky, who provided strong leadership to guide our way. Your Financial Support is Vital! Your continued support ensures that we keep momentum in our campaign to raise public awareness, improve the lives of those afflicted, and ultimately seek a cure to prevent future millions from suffering. There are many different ways to support The Neuropathy Association. Whether through a gift made today or a gift planned for tomorrow, let us work with you to develop an approach that honors your intentions. Ensuring the best match of your charitable wishes to our on-going needs means that together we will beat this disease. For more information on charitable giving options, contact The Neuropathy Association at 212-692-0662. Better Safe Than Sorry: Time and Energy BY RONNIE CHALIF Time plays tricks on all of us. With neuropathy, it takes longer to accomplish less. I recently bought my son an hour glass for the holidays and turned it upside down in the store. Before I turned around, 10 minutes disappeared into the bottom of the glass. Watching time go by was hypnotic. Is it neuropathy? The slowing down of the body or is it aging? The slowing down of clock time? Whatever, perhaps we need more time to accomplish our tasks. Also more energy. To move with neuropathy can be treacherous. The compensation of the body takes energy. Scanning every step takes both time and energy. Walk carefully, Leave earlier to arrive on time. Excuse me… I have to leave for an appointment with my doctor. So I’d better stop here. Good luck. 3 Neuropathy News January 2008 Neuropathy Association Notes NEUROPATHY CENTER OPEN HOUSES HELD IN PHOENIX, ARIZONA AND KANSAS CITY, KANSAS Two of our newest centers in Arizona and Kansas recently kicked off their activities by inviting the local communities to come visit, meet the staff, learn about peripheral neuropathy, and exchange experiences with other patients. On October 3, 2007, Banner Good Samaritan Neuropathy Center in Phoenix hosted an open house that was well received by all in attendance. Dr. Todd Levine (co-director). Dr. David Saperstein (co-director), Kris Irizarry (nurse director) and their team of healthcare professionals along with Tina Tockarshewsky, The Neuropathy Association’s executive director, welcomed patients as well as other Banner healthcare professionals to share with visitors the capabilities offered at the Banner Good Samaritan center. City University Medical Center’s neuropathy center as well as the Association’s executive director Tina Tockarshewsky opened their doors to engage patients and their families in a morning of presentations, information exchanges, and a tour of the facilities. In addition to local greater Kansas City area patients, visitors drove in from Arkansas and Oklahoma, all in an effort to learn more about and get answers for coping with neuropathy. At the Phoenix, AZ, Banner Good Samaritan Neuropathy Center open house: on the left is Amna Mohammad, R.N. and on the right Melissa Ponce, R.N. On December 7, 2007, Dr. Mazen Dimachie (co-director), Dr. Mamatha Pasnoor (co-director), Dr. Richard Barrone (head of the neurology department), their team of medical professionals and researchers at the Kansas AN “INTIMATE EVENING” GATHERING GLITTERS IN NEW YORK CITY Below: Honoree Mrs. I. Heidi Loeb and Dr. Norman Latov, Medical Advisor to The Neuropathy Association. Below (l-r): Tina Tockarshewsky, executive director of The Neuropathy Association, and Honoree Ms. Heidi Loeb. Gathered in support of The Neuropathy Association are (l-r) entertainers Robert White and Karen Akers, co-chair Rev. Mother Dolores Hart, emcee Jim Dale, Tina Tockarshewsky, and co-chair Maria Cooper Janis. In October 2007, an invitation-only fundraising dinner was held at a private club in New York City to raise awareness and support for The Neuropathy Association. Along with Angela Lansbury as Honorary Chair, co-chairs Maria Cooper Janis and Rev. Mother Dolores Hart welcomed guests for an evening emceed by world-renown performer Jim Dale and featuring special performances by cabaret artist Karen Akers and tenor Robert White. The evening celebrated the progress made in raising neuropathy awareness, while also honoring the efforts of three champions working tirelessly on behalf of the neuropathy community: Mrs. I. Heidi Loeb and Ms. Heidi Loeb for their support of the David S. Loeb Neuropathy Center at the University of California-San Francisco, and Mr. Patrick Schmidt, CEO of FFF Enterprises, for his work to ensure proper treatment and care is accessible to those in need of it. The evening raised over $100,000 to support our efforts for the neuropathy community. 4 Above (l-r): Honoree Patrick Schmidt, Tina Tockarshewsky and Dr. Norman Latov. Above: Michael Sloser, Treasurer, and Ronnie Chalif, President of The Neuropathy Association. Photography by Richard Lewin Neuropathy News January 2008 MARK YOUR CALENDARS! MAY 12-16, 2008 IS NATIONAL NEUROPATHY WEEK! As you update your new 2008 calendars, don’t forget to highlight May 1216 as our fourth annual National Neuropathy Week. The third week of May is held for us on the federal government’s official 2008 Calendar of National Health Observances. So be sure to mark your calendars and spread the word in your local community! NEUROPATHY CENTER ADDED IN LOS ANGELES, CALIFORNIA We are excited to announce the addition of another Association-designated Neuropathy Center, this time in Los Angeles under the directorship of 2006 Association award-recipient Dr. W. King Engel along with co-director Dr. Valerie Akanas. Hosted at Good Samaritan Hospital, this newest cen- ter continues to strengthen our network of now eight centers. We look forward to offering the Los Angeles and Southern California communities more opportunities with this new center. For more information, see the Centers’ directory featured on page 6. The Neuropathy Association 2007 Benefactor Members* Thanks to your extraordinary generosity, not only has the number of our Benefactor Members increased by over 50%, but the size of donations has also increased from 2006. Please accept our heartfelt gratitude to all of our contributors for helping us to serve those suffering with neuropathy. Mr. and Mrs. Joseph B. Allegretti Mr. Daniel G. Anderson Mr. and Mrs. Leslie S. Ash Mr. Frank Augsbury Mr. and Mrs. Richard Baker Bank of America/United Way Campaign Mr. Donald Beets Mrs. Emmie Cardwell Bolden Mr. John Boyle The Beverly H. Bremer Trust Mr. and Mrs. Joseph Buckley Dr. Karen Burke Mrs. Ronnie Chalif Ms. Marjorie Chester Mr. David Chleck Dr. Arthur W. Collins Colorado Neurological Institute Columbus Citizens Foundation Corymore Foundation/Angela Lansbury Shaw Mrs. Betsy C. Cosgrove Ms. Helen Crump CSL Behring Cushman & Wakefield, Inc. Ms. Harriet Dennison Mr. Wilbur DeYoung Mr. Dennis Duerre Dr. and Mrs. Selig Eisenberg ENDO Pharmaceuticals, Inc Ms. Stephanie Feld The George and Patricia Ann Fisher Foundation Mr. Michael T. Flora Foresters Mr. David Freeman Dr. and Mrs. James Gardner Ms. Grace Goldberg Ms. Cissel Gott Ms. Beatrice Gougeon Mr. James Hardie Ms. Mary Hegarty Mr. Bernard B. Herman Mrs. Dolores Hope Mr. William K. Howell The Durwood and Susan Huckabay Foundation The Doris and Martin Huffman Foundation Mr. Mordecai Jacobi Mrs. Elaine L. Katz Mr. Jeffrey Katz General (Ret.) P. X. Kelley Kingsbrook Jewish Medical Center Mr. Douglas M. Kinney Dr. and Mrs. Bartley Labiner Dr. Norman Latov Mr. Kenneth Lipper Ms. Heidi A. Loeb Mrs. I. Heidi Loeb Judge Edmund V. Ludwig Ms. Wendy Lumsden The Lumsden Family Foundation The Fred and June MacMurray Foundation Ms. Kathleen Marble Ms. Jan R. Martin Mr. Jack McGouldrick MedPro Rx, Inc. MedStar Health, Inc. The Mellen Foundation The Melrene Fund Mr. Bill Melton Ms. Barbara Middleton Mr. and Mrs. Tom Morgan The Morse Family Foundation The New York Community Trust Octapharma Mr. Robert Patent Mr. Roland Pease Red Hawk Land Company, LLC Mr. Robert Reed Mr. Richard Reuss Lt. Col. (Ret.) Eugene Richardson Robinson Lerer & Montgomery, LLC The Rosensteil Foundation The Marion and Robert Rosenthal Foundation Mr. Stanley Schmulewitz Mrs. Pat Schoenfeld Mrs. Shirley Sherman Estate of Mr. Kenneth Siepman Mr. Joshua Sloser The Thomas W. Smith Foundation Mrs. Betty Soreng Ms. Beverly Sternlieb Mrs. Patrice Stilwell Dr. Judith P. Sulzberger Ms. Joy Swanson Talecris Biotherapeutics Mr. Peter Tishman Tishman Speyer Properties Mr. Robert Toner Ms. Alice Dodge Wallace Ms. Jane M. Waterman The Norman and Vivian Weiden Foundation Mr. Arthur M. Weis The Harvey and Annette Whittemore Foundation Mr. Neal L. Williams Mr. and Mrs. Elliott Wolbrom Mr. Winston E. Wolfe The Zankel Fund *Donors of $1,000 and more as of December 31, 2007 5 Neuropathy News January 2008 Neuropathy Centers Deliver Education, Outreach and Assistance BY TINA TOCKARSHEWSKY We continue to build the groundwork for our network of ten Neuropathy Centers at America’s most prestigious medical schools and institutions. To date, we have laid the foundation for eight centers across the country. The Centers’ directors are enthusiastically carrying out their mission, working closely with The Neuropathy Association to increase local community outreach and provide medical professionals, policymakers and the general public with information about this increasingly pervasive disease. Funding is our biggest challenge, with monies needed to support the staffing and programming that can make the Centers network truly vibrant. When the funding is available, we seek to support each Center’s activities with at least $50,000 per year to provide administration and a nurse coordinator from the host institution to manage day-to-day activities while coordinating activities with the Association. The Association acts as a communications hub, providing educational tools and managerial guidance to encourage pro-patient programs, including seminars and teaching conferences, local continuing medical education (CME) courses and patient support groups. We continue to be hopeful about the long-term potential of this national initiative while working to expand the benefits delivered at the local level. Be sure to tell friends and fellow patients about the centers. Let them know the centers are there to help! Association-Designated Neuropathy Centers ARIZONA Banner Good Samaritan Neuropathy Center Todd Levine, M.D., Co-Director David Saperstein, M.D., Co-Director Kris Irizarry, Nurse Director FLORIDA-JACKSONVILLE University of Florida Neuropathy Center Alan R. Berger, M.D., Director Mindy Grall, Director of Research Karen S. Perrin, R.N., Neuropathy Center Coordinator 1012 East Willetta Street Phoenix, AZ 85006 Tel: 602-239-6515 [email protected] 580 West 8th Street, Plaza 1, 9th Floor Jacksonville, FL 32209 Tel: 904-244-9922 [email protected] http://jax.shands.org/hs/neuro/neuromuscular.asp CALIFORNIA-LOS ANGELES Neuropathy Center of Los Angeles W. King Engel, M.D., Director Valerie Akanas, M.D., Ph.D., Co-Director Good Samaritan Hospital 637 South Lucas Avenue Los Angeles, CA 90017 Tel: 213-975-9950 CALIFORNIA-SAN FRANCISCO University of California at San Francisco Neuropathy Center Jeffrey Ralph, M.D., Director Amy Mahoney, R.N., B.S.N.., Nurse Coordinator 400 Parnassus Avenue, Rm. A837 San Francisco, CA 94143 Tel: 415-353-2312 [email protected] 6 FLORIDA-MIAMI University of Miami Miller School of Medicine Neuropathy Center Kehma Sharma, M.D., Director Gina Gonzalez, R.N., Nurse Coordinator Professional Arts Building, Rm. 609 1150 Northwest 14th Street Miami, FL 33136 Tel: 305-243-7400 [email protected] KANSAS Kansas University Medical Center Neuropathy Center Mazen M. Dimachkie, M.D., Co-Director Mamatha Pasnoor, M.D., Co-Director Vickie Holt, L.P.N., Nurse Coordinator 3599 Rainbow Blvd, Mail Stop 2012 Kansas City, KS 66160 Phone: 913-588-0656 [email protected] MICHIGAN University of Michigan Neuropathy Center Eva L. Feldman, M.D., Ph.D., Director Timothy L. Funckes, R.N., B.S.N., Nurse Coordinator Taubman Center 1914/0316 1500 East Medical Center Drive Ann Arbor, MI 48109 Tel: 734-763-7274 For Appointments: 734.936.9020 Fax: 734-763-7275 [email protected] http://www.med.umich.edu/neuro/clinical/neuropathy.htm NEW YORK Peripheral Neuropathy Center New York Weill Cornell Medical Center Weill Cornell Medical College New York-Presbyterian Hospital Norman Latov, M.D., Director Corinna Cassillo, R.N., B.S.N., Nurse Coordinator 635 Madison Avenue, Suite 400 New York, NY 10022 Tel: 212-888-8516 [email protected] http://www.cornellphysicians.com/periphneu/ Neuropathy News January 2008 Supporting Support Groups Part I: Getting Started BY IRENE H. BEER The Neuropathy Association is proud of its 120 volunteer-led support groups throughout the US and Canada. This network provides members with an opportunity to learn from each other, develop friendships, and hear professional speakers familiar with peripheral neuropathy (PN). Six years ago, I was a snowbird in Florida who wanted to start a local support group. I called Paul Guidos at The Neuropathy Association and asked him to help me find members living in my area. With Paul’s help, I met Morty Baum, who agreed to serve as a co-leader. Balance, Strength and Mobility.” Both speakers were excellent, and answered a lot of questions. The group is actively engaged each meeting, and I am glad Steven and I have kept it moving along so well. Remember, The Neuropathy Association is very supportive, and can provide you with literature on staring a group and connecting with members in your area. Give Paul Guidos a call at (212) 692-0664 or e-mail him at [email protected]. It’s very satisfying and pleasurable to meet others with PN and help them learn more about it. After looking around, Morty and I found a library to provide a room for us once a month at no charge. Local Association members were contacted, and we were ready to start our group. The local newspapers featured a section on Support Group Meetings, where we were able to advertise. As our group grew, the space became over-crowded. STARTING A SUPPORT GROUP If you are considering starting a support group in your area, you will want to incorporate ideas from other support group leaders— their tips and tricks, do’s and don’ts. Irene Beer offers the following lessons she has learned from her own experiences. I spoke with my local neurologist about our space problem. He told me that the hospital he was connected with had a conference center located immediately opposite the main hospital’s entrance. The center was a large space with microphones, comfortable seating, and film screens—excellent meeting facilities. The hospital even offered to provide cold drinks and snacks, and send out monthly notices for us. We were delighted! Since then, I have moved back to New York City, where I was recently asked to start another support group. I talked to friend and fellow IVIG recipient, Steven Smith, about getting the group started. We needed a place, but many public spaces in NYC charge money. As we discussed our dilemma in the infusion room, a fellow patient offered us a conference room. He was a member of a large law firm, conveniently accessed by all forms of transportation. Steven and I were thrilled! I called Paul Guidos again, and notices went out to New York City members announcing our meeting. At our first session, our host provided a table with bottles of water, cups, ice, coffee and tea, cakes, fruit plus other amenities including copying. Needless to say, we were very pleased. We began our meeting by having everyone introduce him/herself and talk about their PN experience. Pain was the major concern facing the group, and attendees were eager to exchange information, ask questions and find out about medications. In recent months, we have had two wonderful speakers. A doctor from The Neuropathy Center at Weill Cornell in New York City spoke about “Wellness Programs for the PN Community,” and our second speaker— my physical therapist—spoke on “Improving Function Despite PN: Irene’s Support Group Tips Starting a support group is about reaching out to people who share your interests, supporting and promoting a cause by addressing each other’s needs, and building a community. • • • • • • • • • • • It requires time, patience and plenty of energy! But it’s worth it Seek donated space in a library, hospital convention center or business. Take transportation and accessibility into account when finding a place. Ask. Some places may make copies, mail notices, and provide refreshments. Tap your own resources for speakers—your neurologist or therapists. Most papers have a section to advertise local group meetings. Use it. Almost everyone wants to discuss their pain, share info and get feedback. Provide resources—pain information, articles and contacts. Delegate. Several leaders manage work more easily and prepare better. Divide simple tasks like attendance, copying and providing refreshments. Listen to what the group needs, provide it and be flexible and creative! We look forward to bringing you more ideas and invaluable “lessons learned” from support group leaders in future issues. 7 Neuropathy News January 2008 Self-Help Support Groups in the U.S. and Canada Support groups provide a much-needed support network for sharing and learning. These groups, run by their members, meet to exchange common experiences and knowledge, and offer one another strength and hope. If you do not find a group in your area, contact us for suggestions—or even ALABAMA Frank Broadway, Jr. 334-244-2020 ARIZONA Mesa Marilynn Falk 480-354-2231 [email protected] Scottsdale Donna Brower 480-312-7984 [email protected] Tucson Alex MacDonald 520-749-3583 [email protected] Carol Rohlinger (CL) 520-290-9093 [email protected] ARKANSAS Mt. Home Anita Hayden 870-425-4701 [email protected] CALIFORNIA Auburn - Day Terry Stennis 916-663-3108 [email protected] Auburn - Day Charlene Amos 530-885-9865 [email protected] Auburn - Evening Bev Anderson 530-389-2416 [email protected] Auburn - Evening Grant Whitney 530-887-9881 [email protected] 8 consider helping us start one in your local community. You might be surprised where the initiative takes you! For more information, please contact Paul at 212-692-0664 or [email protected]. Berkeley Alan Dampsey 510-527-3568 [email protected] Napa Ron Patrick 707-257-2343 [email protected] San Jose Stan Pashote 510-490-4456 [email protected] Los Angeles Velda DeCosentine 310-485-0357 [email protected] Concord Ernette Rivera 925-889-2484 [email protected] Oakland Kathleen Nagel 510-653-8625 [email protected] Santa Cruz Mary Ann Leer 831-477-1239 [email protected] San Diego Jean Nurding 619-435-0850 [email protected] Concord Joe Burbulis 925-930-0300 [email protected] Placerville Arlene Middlebrook 530-626-1089 [email protected] Santa Rosa William Quarante 707-544-3238 Morningside Jack McGouldrick 714-256-8273 [email protected] Davis Martha Chandley 916-371-1125 [email protected] Placerville Frank Roscoe 530-647-0777 [email protected] Elk Grove Michael Colozzi 916-421-8103 [email protected] Redwood City Annette DeVost 650-595-2478 [email protected] Elk Grove Susi Watson 916-354-0483 [email protected] Redding John Wright 530-337-6570 [email protected] Folsom Lorraine Morosi 916-984-4302 [email protected] Redding Anne Handel 530-241-6517 [email protected] Grass Valley Sally Hearn 530-268-1017 [email protected] Roseville Mary Lou Ward 916-772-5598 [email protected] Jackson Darlene Jarnigan 209-296-1760 [email protected] Roseville Marilyn Larson 916-771-8435 [email protected] Lincoln Bev Anderson 530-389-2416 [email protected] Sacramento Charles Moore 916-485-7723 [email protected] Livermore E. Lorene Stack 925-447-6158 [email protected] Monterey Don & Ann Trout 831-372-6959 [email protected] Sacramento Myke Taylor 916-487-2903 [email protected] San Francisco Amy Mahoney 415-502-5065 [email protected] CL indicates Co-Support Group Leader Sonora Ed Minium 209-586-3702 [email protected] Stockton Case Klooster 209-463-5985 [email protected] Stockton Lynda Icochea 209-832-1480 [email protected] Truckee Bev Anderson 520-389-2416 [email protected] Walnut Creek Nancy Ostrander 925-930-9524 Los Osos Alexander Morrison 805-534-1215 [email protected] Costa Mesa Dr. Marc Spitz 562-799-0656 [email protected] Chico Dorothy Rolls 530-899-6944 Clare Brown (CL) 530-343-8387 Stockton Case Klooster 209-463-5985 [email protected] COLORADO West Sacramento Sandra Vinson 916-372-6093 [email protected] Woodland Donna 530-661-3705 Yuba City Nancy Escudero 530-673-3698 [email protected] Yuba City Ken Lux 530-673-3468 [email protected] Denver Dorothy Miller 303-814-2112 [email protected] Colorado Springs Robert A. Lowes 719-488-5605 [email protected] CONNECTICUT Groton Linda McIntosh 860-460-6445 [email protected] Neuropathy News DELAWARE Wilmington Frank Castelli 302-475-1706 [email protected] FLORIDA Bradenton Neal Kuyper 941-761-0179 [email protected] Broward Eugene Richardson 954-523-2987 [email protected] Indian River County Dr. John Lawlar 239-573-1001 Martin County Lou Nielsen 772-287-1292 Palm Beach Samuel Grundfast 561-964-0147 [email protected] Duval County Dr. Alan Berger 904-244-9922 Ladylake Jean Ganske 352-753-8382 [email protected] GEORGIA Atlanta James Griesmer 404-378-3516 [email protected] Hilary Hargreaves (CL) 404-378-4587 [email protected] IDAH0 Boise Patricia Montross 208-395-1547 [email protected] ILLINOIS Quad Cities Mary Kay Keemle 309-755-1063 [email protected] January 2008 Chicago Kathy Slottag 773-693-3578 [email protected] Orleans Jackie Stowell 508-255-7697 E-Group Joseph Moniz 508-672-8824 [email protected] IOWA Dubuque Bert Muir 563-583-2536 [email protected] MICHIGAN East Michigan Mary Hall Price 248-819-7547 Mary.Hall-Price@ accredohealth.com Cedar Rapids Kitty Chandler 319-378-8403 [email protected] Len McCulloch 248-474-2763 KENTUCKY Bowling Green Eric McGriff 270-783-0805 [email protected] Grand Rapids Dorothy Teesdale 616-897-9794 [email protected] Louisville Debbie Goldstein 502-426-4399 [email protected] MINNESOTA Minneapolis Lois Martin 952-941-5372 [email protected] Peggy Smith (CL) 502-239-7239 [email protected] Baton Rouge Richard Palecki, DPM 225-291-0093 Jennifer Sigler (CL) 225-906-4819 [email protected] Scott Hunt 877-373-7817 [email protected] MAINE Kansas City Shirley J Lynn 913-299-9873 [email protected] Southern Maryland David Spore 301-737-0623 [email protected] NEW JERSEY NORTH DAKOTA Englewood Mary Robertson 973-226-1535 [email protected] Minot Richard Kraft 701-776-5127 OHIO Tom McCullum (CL) 201-692-9313 [email protected] Hamilton Bill Giovannetti 609-587-7215 [email protected] Fran Burns (CL) 609-298-8135 [email protected] Brick Fontainne Gatti 908-233-9709 [email protected] Cincinnati Shirley Planet 937-433-1296 [email protected] Sharon Wilson (CL) 937-379-2572 Cleveland Kay Seawright 330-468-2526 [email protected] Miamisburg Sandy Daws, LPN 937-866-9089 [email protected] NEW YORK St. Louis Susan Bonnell 877-373-7817 [email protected] MARYLAND Greensboro Retta Gray 336-852-8489 [email protected] OKLAHOMA MISSOURI LOUISIANA Bangor Area Suzanne Mock 207-862-6671 [email protected] Reno Marsha J. Campbell 775-851-0499 [email protected] MONTANA Billings P. R. Crellin 406-655-5471 [email protected] NEBRASKA Manhattan Irene Beer 212-787-2767 [email protected] Rick Wagonheim (CL) 917-873-0803 [email protected] Brooklyn Lisa Volpe-Campisi 718-232-4179 [email protected] Rochester John McNeill 585-247-5543 [email protected] Mohawk/Utica Annette Reeder 315-866-5227 [email protected] Parkville Dorothea Svilar 410-668-0841 Lincoln Sandy Behrens 402-483-4908 [email protected] MASSACHUSETTS NEVADA Raleigh Marion Tice 919-872-2360 Northshore Werner Paster 978-479-4339 [email protected] Las Vegas Kim Heffner 702 -452-8277 [email protected] Pittsboro Vera Reece 919-542-7272 [email protected] CL indicates Co-Support Group Leader NORTH CAROLINA Oklahoma City John (Jim) Miller 405-728-4487 [email protected] Janice Coleman (CL) 405-373-2286 [email protected] Tulsa Mary Lou Harkins 918-830-0157 [email protected] OREGON Corvallis Betty McCarty 541-926-1212 [email protected] Milwaukee Deegee Ingle 503-652-6489 PENNSYLVANIA Erie Louise Schulze 814-838-2556 [email protected] (continued on page 10) 9 Neuropathy News January 2008 Self-Help Support Groups in the U.S. and Canada PENNSYLVANIA con’t Havertown Donna M. Elberson 610-446-0792 [email protected] Broomall Denise Metz 610-356-4719 [email protected]. SOUTH CAROLINA Charleston Richard Marks, Jr. 843-884-3573 Columbia John Watkins 803-256-1957 Mary Spradlin (CL) 803-782-5823 [email protected] Corpus Christi Richard A Bates 361-992-4314 [email protected] Fort Worth Ken Hestand 817-737-4735 [email protected] Wichita Falls Joe Castelli 940-692-2807 [email protected] Houston Area Ann Green 281-556-1415 [email protected] Tarrant County James Beard 817-318-1639 [email protected] VIRGINIA Greensville Patsy Young 864-877-0702 [email protected] Virginia Beach Robert M Williamson 757-518-8086 [email protected] SOUTH DAKOTA WASHINGTON Gregory Patti Nachtigal 605-835-8394 [email protected] Northwest William M. Ouweneel 360-676-0376 [email protected] TENNESSEE WISCONSIN Knoxville Paula Isenberg 865-945-3810 [email protected] Fox Valley Michael Barklow 920-380-0218 [email protected] Loudon County James Fella 865-458-1781 [email protected] Ron Fafnis (CL) 920-759-0022 [email protected] Memphis Herbert W Smith 901-843-3098 [email protected] TEXAS Fort Worth Mary Heyduck 817-429-6298 [email protected] 10 Milwaukee Caroline Meitler 262-968-4631 [email protected] Mary Yellick 800-272-3666 WYOMING Casper Doris Hlava 307-234-1976 [email protected] CANADA Calgary, AB Val Shaw-Lewis 403-831-2187 [email protected] Fredericton, NB Sharon Van Abbema 506-454-1551 [email protected] (continued from page 9) Peterborough, ON Glenn Rogers 705-741-0044 [email protected] SWEDEN Stockholm Hellen Ohlin 46 (0) 8 65139 00 [email protected] Spread the Word: Ask Your Doctor to Feature Association Brochures! Another easy way you can help us and help others is to ask your doctor to make Neuropathy Association brochures available for their patients. Simply drop us a note at [email protected] with your mailing address, and we’ll send you a set of membership brochures to take to your doctor’s office. Or call us at 212-692-0662 to ask for brochures. It’s a quick way you can make a big difference! Stay Up to Date with www.neuropathy.org! In-between newsletters, be sure to keep up with the latest developments by visiting www.neuropathy.org. Whether it’s visiting with other patients on the bulletin board or reading about research and advocacy efforts, you’re sure to find something new each time you visit, so be sure to stop by regularly! Peripheral Neuropathy: When the Numbness, Weakness and Pain Won’t Stop by our own medical advisor, Dr. Norman Latov (Limited Quantities at $10 each) This special price is below retail, and all proceeds go directly to the Association. Consider sharing this straightforward volume with others so they might learn more about neuropathy as well. Neuropathy News January 2008 Optimizing Wellness Part II: Understanding Pain BY BRIDGET T. CAREY, M.D., CORNELL WEILL PERIPHERAL NEUROPATHY CLINIC This is the second in a series of articles focusing on optimizing wellness for people living with neuropathy. Pain is an essential biological function that helps us survive and thrive. Its purpose is to alert us to tissue damage occurring somewhere in our bodies, so we can move, adjust our position or behavior, or do whatever possible to stop the damage. For example, if you cut your finger chopping an apple, you realize it first because you feel pain. As a result, you stop, examine the wound, and decide to put on a band-aid or go to the emergency room. basic function to ensure survival. This response is true for acute, sudden pain, as well as chronic pain like the pain that occurs with neuropathy. You can choose to refocus your attention upon other matters; however, as long as the pain continues, your attention centers will continue to be pulled back to that pain to some degree. This is why people with chronic pain often find it difficult to concentrate. Pathways of Pain Pain is Multi-Faceted On the surface, this seems straightforward. However, the way our nervous system generates and processes pain is multi-faceted. Pain hurts, both physically and psychologically. In addition to the experience of hurting, numerous linked neurological and physiological processes occur. While not as immediately distressing, these processes contribute to the overall dysfunction, disability, and suffering associated with chronic pain. By illuminating the numerous neurological processes we can better understand its power over our lives. Then, we can formulate strategies to disconnect and uncouple these responses, weakening the effects pain inflicts upon our day-to-day existence. Pain Sends an ‘Alarm’ What exactly is pain? When damage occurs in the body, specialized sensory nerves activate, like an alarm. These nerves convey this alarm to nerve cells in the spinal cord. In turn, these spinal nerve cells send a message to a part of the brain called the thalamus, which acts like a relay station. It integrates all sorts of incoming information and decides what to do with it. In the case of pain, the thalamus sends messages to several different areas of the cerebral cortex, each serving a specific role. For example, in response to a pain signal, the thalamus sends a message to specialized regions in the brain that direct and maintain our attention. In other words, pain forcibly redirects the brain’s centers of awareness and attention away from whatever you are doing prioritizing a possible threat to life or limb. It is worth noting this is not a gentle re-direction; rather, more of a forcible one. What if while cutting that apple you are watching a riveting murder mystery and about to find out who the killer is? No matter how enthralled you are, the moment your finger’s cut, the mystery recedes and your attention is pulled to your finger. Your re-direction of attention is an involuntary, In addition to activating the brain’s attention and concentration centers, pain pathways strongly connect to the brain’s centers for memory and learning. This serves to protect our own well-being: if you experience hurt the first time you touched a red-hot piece of metal, you will probably think twice before touching a similar object. We fear things we know can hurt us; the emotion encourages us to avoid these things. In chronic pain, however, these connections are less helpful. Many types of chronic pain, neuropathy included, have no easily avoidable pain-causing agent, and the pain continues to be associated with anxiety and fear. Often, one comes to fear the pain itself. Over time, a sense of helplessness and hopelessness tends to develop that reinforces our fear. The brain learns: the more a pathway is used, the more efficient the circuitry becomes. With chronic pain, connections strengthen as they are used again and again. Being in pain becomes easy—even normal. The good news is that while we cannot control the “alarm” input coming from pain, we do have a measure of control over how the brain allocates resources. Through using voluntary thought, we can retrain our brain to change its default connections. “Thinking” consists of using our brain’s circuitry. Consequently, we can work to change old paths of least resistance by creating new ones. This will not eliminate pain, but it may lessen some of the suffering. Calming Pain Studies have addressed whether exercises such as yoga, tai chi, and meditation might “uncouple” pain. Each may improve people’s experience of pain. The most common outcome is participants are aware they are in pain; yet, it does not bother them as much. They feel better and are happier. (continued on page 13) 11 Neuropathy News January 2008 Letters to the Editor Your letters teach and inspire us all! Please keep your personal stories, comments and tips coming. Email us at: [email protected]. Or write to us at: Editor, The Neuropathy Association, 60 E. 42nd St., Suite 942, New York, NY 10165. Be sure to include your name, address and phone number on your letter. A Member Reflects Thank you so very much for sending the information to me. I couldn’t be more proud to see how far this organization has come in the last 10 years. I have to say that when I was first told of my illness after a year of nobody listening—most thought I just wanted pain medicine—the web site was a godsend for me. I do remember reading about the people who had it for so long and thinking that I would never be able to last that long with this disease. Well, I’m glad to say that I am still here and have no plans of leaving this world soon. So, thank you for all the help in learning I was not alone. Marjorie F. Keys to Managing My Foot Pain I have had neuropathy for eleven years. I have had extensive tests to determine the cause, and that has led to a keeping my pain and related symptoms at a manageable level. Today, I am retired, and at 67 years old, I can ski downhill, teach week-long sailing courses, drive our car long distances, and work in our yard. Thank you for keeping me posted with your newsletter. David S. Neuropathy E-News Successfully Launches Editor’s note: Responses to our new e-newsletter, launched in August 2007, have been overwhelming. These are just a few of the comments received: Thanks so much for the excellent publication distributed by e-mail. I predict it will be a big hit and produce a tremendous increase in the sharing of vital information to those of us with peripheral neuropathy. Guy B. Some Support and Relief I was diagnosed with idiopathic peripheral neuropathy 6 years ago. I feel severe arthritis of the spine caused my neuropathy. My feet began to burn and my legs began to sting. My medication has been problematic. One cause blurred vision. Another caused me to heat up like a furnace and my legs felt like a hot dog on a spit. I tried topical creams which seemed to help. Another thing that I found helped a little were support stockings. June B. These letters are examples of the many letters we receive. If you don’t see your letter here, it could appear in a future issue. We reserve the right to edit letters for space and clarity. Any products mentioned express the sole opinion of the writer, and do not represent an endorsement by The Neuropathy Association. Readers are advised to consult with their physician before considering any new treatment or regimen. Thank you for Neuropathy E-News: attractive, efficient, and informative. Bob W. I have been, and will continue to be, a contributor. I just received your e-mail, which is a worthwhile and much needed source of information! The material is excellent, and will be of great benefit to everyone involved...from patients to healthcare providers. Hopefully, we can find a cure for this almost forgotten and little understood condition. David E. ….I appreciate the e-news. Printed newsletters go on a stack of periodicals I eventually get to…but I read emails each morning with my first cup of coffee. What a treat to find the Neuropathy E-News waiting for me this morning. I read every word, and forwarded the information about GoodSearch to family and friends…. Patti L. © 2003 The New Yorker Collection from Cartoonbank.com. All Rights Reserved. 12 Neuropathy News Ask the Doctor In this column expert neurologists answer your questions about neuropathy—usually one question per issue, and more when we are able. Please send your questions to “Ask the Doctor” c/o Neuropathy News, The Neuropathy Association, 60 East 42nd Street, Suite 942, New York, NY 10165-0930. DEAR DOCTOR: In 2002, I was diagnosed with autonomic neuropathy after believing I had fibromyalgia….I know little about this disease other than it is an auto-immune disease. I also have severe arthritis in my spine with severe cervical stenosis. Since I have both of these problems, I get very confused as to which problem is causing my pain and fatigue. I had a transient ischemic attack (TIA) in June 2006, which is believed to have been caused by a newly discovered patent foramen ovale (PFO) in my heart. However, my neurologist seems to believe it might have been the autonomic neuropathy which caused the TIA. My PFO has not been fixed….I need someone to help me with this disease and give me some advice and information….By the way, I am a 64-year old woman (who looks younger), and have five grandchildren I enjoy seeing and doing things with. So any help is appreciated. Thank you, Marion L. DR. LOUIS H. WEIMER ANSWERS: Many of our automatic and unconscious body functions are controlled in part by a complex system comprising our autonomic nerves and related brain areas. Several forms of peripheral neuropathy can affect or disrupt autonomic nerves. In most cases, the problem is restricted to the same sensory (sensation) and motor (strength) areas affected by the neuropathy, usually the feet and lower legs. The most common autonomic changes affect skin and blood flow in the area, often producing dry, cold, discolored feet. The skin often becomes thinner and shiny due to a loss of normal body oil production. Sweating in the local area is also reduced, sometimes forcing other areas of the body to compensate by sweating excessively. Some of the causes of neuropathy, including diabetes, can produce more widespread and severe autonomic problems such as drops in blood pressure (orthostatic hypotension), bladder disturbances, gastrointestinal alterations, sexual dysfunction, reduced eye responses to light, and other similar dysfunctions. There are recognized immune-mediated causes of autonomic neuropathy, but they comprise only a minority of cases. Autonomic neuropathy can be challenging to both diagnose and prove; however, non-invasive methods of testing are available in many centers. Treatment depends on the underlying cause, with drops in blood pressure the most common symptoms requiring treatment. Some January 2008 blood pressure drops can occur without producing symptoms and may go unnoticed. Checking blood pressure while reclining and then, again, after 2-3 minutes of standing is the optimal routine bedside test. More subtle but frequent blood pressure declines after standing—especially with increases in heart rate—can produce fatigue mimicking chronic fatigue syndrome or fibromyalgia. However, these symptoms should be tied to standing and not be present all of the time (orthostatic intolerance syndrome). Pain is a more complex symptom that can be produced by many separate causes. In your specific case, there are not sufficient details to tell whether the diagnoses are accurate and autonomic neuropathy is the probable cause of your symptoms. Dr. Louis H. Weimer is Co-Director of the Columbia Neuropathy Research Center and Associate Clinical Professor of Neurology at Columbia University. Optimizing Wellness continued from page 11 The idea is to alter the constant activation of the attentional and emotional centers in response to the pain signal by recruiting them for other activities. Studies suggest the most favorable of these may be “Transcendental Meditation.” This type of medication includes any meditation using a “mantra”—a word or phrase repeated many times. These words may be recited silently or aloud. Transcendental Meditation works for pain by inducing a calm, restful state that combats anxiety while simultaneously requiring constant attention to the mantra, consequently capturing the brain’s frontal lobe centers of concentration and attention. Pain, though we may work to clam it, is a necessary survival function pulling our attention when the body is damaged. While we cannot control our pain “alarm,” we can redirect our response through voluntary thought. Meditation may help by giving us a way to lessen some of the suffering from pain and improve our quality of life. Meditation Exercise for Pain • Pick a mantra that works for you—a line from a poem or writing that speaks to you. • Dedicate a quiet time and place where you will be undisturbed for at least 15 minutes. • Sit comfortably and recite your mantra silently in your head, or tonally aloud. • Have patience. When your mind wanders, gently re-direct attention to your mantra. • Dedicate 15 minutes daily to your practice and try to stick with it for at least 30 days. 13 Neuropathy News January 2008 When Neuropathy Affects Driving Your Options When Driving Safely is Compromised by Neuropathy BY MARY BETH MEYER, O.T.R., C.D.R.S., DRIVER REHABILITATION OF THE HUDSON VALLEY We often take for granted our ability to get in the car and go whenever we want. Until we experience a change. If neuropathy has caused a loss of sensation, pain, weakness or incoordination, it doesn’t mean you have to lose your independence! But it might be time to investigate if you need to modify your driving. There are professionals available to help you maintain your safety and independence. First Assess Your Challenges Speak to your doctor about the changes you are experiencing. Discuss concerns he or she has about how these changes may affect your mobility and driving. Numbness in your legs or feet can cause difficulty in determining if your foot is placed on the gas or brake pedal. And, of course, accidentally confusing these can be disastrous! Reduced sensation can cause your foot to slip off the brake pedal while stopped in traffic, causing the car to suddenly roll forward. Weakness in your legs may cause a “foot drop” which makes it difficult to lift your foot from the gas to the brake. Weakness or loss of feeling in your hands can make turning the steering wheel or shifting gears more challenging too. Find Solutions to Your Challenges A “driver rehabilitation specialist” is a certified professional specially trained to work with individuals with physical limitations and help them maintain mobility in the community and safety in driving. A driver rehab specialist can evaluate your needs and recommend adaptive equipment to use in your vehicle to compensate for your specific area of difficulty. For example, hand controls for gas and brake are available instead of using your feet on the pedals. A special cover on the steering wheel may give you a better grip to turn the wheel. If you use a motorized scooter when you go out, special lifts can help get it in your vehicle. The key is to consult with a specialist who can assess your needs and recommend which modifications are right for you. In most cases, you will have an opportunity to try the adaptive equipment and be trained in the correct way to use it. Get the Right Adaptive Equipment The driver rehab specialist can provide you with a list of dealers who modify motor vehicles and companies that sell adaptive devices. It is very important you purchase adaptive equipment from dealers certified and trained in installing these products. Check to be sure they warranty what they sell and can service it if necessary. It is risky to purchase and install this type of equipment through the internet or an unreliable seller. 14 Once you have the vehicle modified to meet your needs, the driver rehab specialist can train you in using the equipment and make sure you’re comfortable and safe with the changes. Some devices (hand controls for example) take training and practice to learn to use. Plan for the Future if Your Condition May Worsen If you are thinking about buying a wheelchair or scooter, consult with a mobility specialist who can tell you if the equipment will fit in your vehicle. A driver rehab specialist can also guide you in assessing what type of vehicle may be appropriate for you. The size, dimensions and features of your wheelchair or scooter makes a difference in which vehicle you can buy. Before buying, consider the ease of getting in and out of the vehicle. Is there adequate parking at your home for a wheelchair accessible vehicle if one is needed? Will the vehicle meet your family needs as well? The process of adapting to changes in your condition does not need to be overwhelming. Seek the skills of the many professionals who are available to assist you in maintaining your safety and independence. To locate a driver rehabilitation specialist in your area. contact: ADED - The Association for Driver Rehabilitation Specialists (877) 529-1830 www.aded.net For information about mobility equipment dealers, contact: NMEDA - National Mobility Equipment Dealers Association (800) 833-0427 www.nmeda.org/consumers.htm You may also be able to find a driver rehabilitation specialist through a local rehabilitation hospital. Your medical insurance may cover some of the expense of the evaluation or adaptive equipment. You may need a doctor’s prescription to receive services. Happy New Year! As we begin 2008, The Neuropathy Association would like to send you and your families all our best wishes for the New Year ahead. Our sincerest thanks for your support as we continue our endeavors on your behalf. Hopefully, together, we can make 2008 the year that finally brings a cure! Neuropathy News January 2008 A Constructive Engagement with the FDA on Regulation, Advocacy and Research FDA Invites Open Exchange with Representatives from Neurological Disease Advocacy and Research Organizations BY NATACHA T. PIRES The Neuropathy Association was invited to a meeting last October by The U.S. Food and Drug Administration’s (FDA) Office of Special Health Issues (OSHI). The focus was building relationships between the FDA and key groups representing the neurological diseases’ patient community. Approximately 50 patient and scientific organizations attended, including Federal health agencies like the National Institutes of Health (NIH). The meeting explored the FDA’s role in clinical trials and drug approvals, OSHI’s role in developing treatments for patients with neurological disorders, and encouraged participation by researchers and advocacy groups in the formulation of FDA policies and procedures. Theresa Toigo, R.Ph., M.B.A., director of OSHI, started by explaining the IntraAgency Neurology Working Group’s role in enhancing neurological disease communication within the FDA. Neurological products are comprised of drugs, devices, biologics, and combination products; each having a different review center within the FDA. The Group provides a forum between review centers for sharing technical and regulatory expertise as well as identifying opportunities for patient advocacy groups to get involved. Critical Path Initiative in Neurology Armando Oliva, M.D., deputy director of Bioinformatics from the FDA’s Office of Critical Path Programs, reviewed steps taken and challenges faced in accelerating and simplifying the medical product development process. In 2004, a nationwide “Critical Path Initiative” was launched to support innovation in three areas: • Biomarker Development – The FDA’s Biomarkers Consortium strives to develop biological markers for new developments in drugs, diagnostics and treatment. • Clinical Trial Modernization – This initiative focuses on increasing efficiencies in regulation of clinical research trials, design and methodology. • Bioinformatics Optimization – By optimizing storage for new and existing data, an e-platform could link healthcare findings to scientific information in the field. Consideration of Risks for Preventive/Disease-Modifying Medical Products Russell Katz, M.D., FDA’s Neurology Products Division Director, gave a compelling overview of risks involved in product development, including how the FDA evaluates risk and balances identifiable and unidentifiable risks. Katz emphasized the final risk/benefit decision process is, at best, a collective exercise in judgment. Patient input plays a crucial role when the FDA considers significant risks associated with an investigational drug’s “acceptability.” In serious conditions, Katz says significant and fatal risks may be deemed “tolerable” as long as informed consent appropriately explains the risk, the risk is sufficiently rare, and all steps (including risk management strategies) are taken to protect the patient. (continued on page 16) ✁ Pass It Along! Name: _____________________________________________ Do you know someone who might benefit from this newsletter or a membership in The Neuropathy Association? Then pass the newsletter along! Address: ____________________________________________ __________________________________________________ __________________________________________________ BECOME A MEMBER Telephone: __________________________________________ Contributing Member $35 $50 $75 Sponsoring Member $100 $250 $500 Benefactor $750 Annual Contribution $1,000 or more General Member Give what you can: $__________ Enclosed is my check or money order made out to The Neuropathy Association, Inc. for a total of $______________ Please bill my credit card for a total of $ ___________________ American Express MasterCard Visa Discover Card Number: ________________________________________ Please send payment and this form to: The Neuropathy Association, Exp. Date: _______________________ 60 East 42nd Street, Suite 942, New York, NY 10165. Signature: ___________________________________________ 15 Neuropathy News January 2008 Patient Involvement in the Regulation of Medical Products continued from page 15 Patient Advocate Involvement and Influence in the Regulatory Environment for Medical Products Regulatory Issues in Medical Devices Ann Costello, Ph.D., D.M.D., pain fellow at the FDA’s Center of Devices and Radiological Health, outlined the regulatory pathway for medical devices approval. She underscored the growing need to collaborate with academia, industry and patient advocates to grasp the scope of medical therapies amidst today’s rapid and complex advances. Outreach and Dialogue at the FDA An overview of the FDA’s outreach efforts for patient and scientific organizations to address the regulatory process was presented by Celia Witten, Ph.D., M.D., FDA’s Office of Cellular, Tissue and Gene Therapy Director. Efforts included scientific workshops, public forums, advisory committee meetings, scientific and medical association conferences, as well as separate meetings with scientific and industry associations on issues and confidential meetings with manufacturers on product plans. This panel discussion was moderated by David Banks, R.Ph., Ph.D. from FDA’s OSHI. The three panelists—Diane Dorman (The National Organization for Rare Disorders), Steve Gibson (The Amyotrophic Lateral Sclerosis Association), and William Thies, Ph.D. (The Alzheimer’s Association)—shared their perspectives on the orphan drug program’s success, reassessing overreaction to risk, and finding issue-oriented input. The panel showcased synergies achieved and goals to strive for when neurological disease advocacy organizations and the FDA collaborate. Groundwork was laid for neurological diseases organizations to help the FDA modernize and transform product development. The Neuropathy Association looks forward to advocating on your behalf for bringing new products sooner (while monitoring risks), scrutinizing safe usage of products reaching the market, and providing targeted diagnoses and treatments. The Association hopes to provide updates on future FDA exchanges. Paid Advertisment 16
© Copyright 2024